Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity

Toxicological Sciences

Volumn 75, Issue 1, 2003, Pages 169-180

  Card, Jeffrey W ^a   Racz, William J ^a   Brien, James F ^a   Margolin, Solomon B ^b   Massey, Thomas E ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b Marnac Inc   (United States)

Author keywords

Amiodarone; Fibrosis; Inflammation; Lung; Mitochondria; Pirfenidone

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BLEOMYCIN; HYDROXYPROLINE; LACTATE DEHYDROGENASE; MESSENGER RNA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; FIBROGENESIS; GENE EXPRESSION; HAMSTER; HISTOPATHOLOGY; LEUKOCYTE MIGRATION; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; LUNG TOXICITY; MALE; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PNEUMONIA; TOXICITY TESTING;

ACUTE DISEASE; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLEOMYCIN; CRICETINAE; DISEASE MODELS, ANIMAL; HYDROXYPROLINE; MALE; MEMBRANE POTENTIALS; MITOCHONDRIA; OXYGEN CONSUMPTION; PULMONARY FIBROSIS; PYRIDONES; RNA, MESSENGER; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMALIA; CRICETINAE;

EID: 0042883823     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfg167     Document Type: Article

References (40)

1. Blake, T. L., and Reasor, M. J. (1995a). Acute pulmonary inflammation in hamsters following intratracheal administration of amiodarone. Inflammation 19, 55-65.
2. Blake, T. L., and Reasor, M. J. (1995b). Pulmonary responses to amiodarone in hamsters: Comparison of intratracheal and oral administrations. Toxicol. Appl. Pharmacol. 131, 325-331.
3. Bolt, M. W., Card, J. W., Racz, W. J., Brien, J. F., and Massey, T. E. (2001). Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol. Exp. Ther. 298, 1280-1289.
4. Bolt, M. W., Racz, W. J., Brien, J. F., Bray, T. M., and Massey, T. E. (1998). Differential susceptibilities of isolated hamster lung cell types to amiodarone toxicity. Can. J. Physiol. Pharmacol. 76, 721-727.
5. Cantor, J. O., Osman, M., Cerreta, J. M., Suarez, R., Mandl, I., and Turino, G. M. (1984). Amiodarone-induced pulmonary fibrosis in hamsters. Exp. Lung Res. 6, 1-10.
6. Card, J. W., Lalonde, B. R., Rafeiro, E., Tam, A. S., Racz, W. J., Brien, J. F., Bray, T. M., and Massey, T. E. (1998). Amiodarone-induced disruption of hamster lung and liver mitochondrial function: lack of association with thiobarbituric acid-reactive substance production. Toxicol. Lett. 98, 41-50.
7. Card, J. W., Leeder, R. G., Racz, W. J., Brien, J. F., Bray, T. M., and Massey, T. E. (1999). Effects of dietary vitamin E supplementation on pulmonary morphology and collagen deposition in amiodarone- and vehicle-treated hamsters. Toxicology 133, 75-84.
8. 1 gene expression but not prevention of mitochondrial dysfunction. J. Pharmacol. Exp. Ther. 304, 277-283.
9. Coker, R. K., and Laurent, G. J. (1998). Pulmonary fibrosis: Cytokines in the balance. Eur. Respir. J. 11, 1218-1221.
10. Cooper, J. A., Jr. (2000). Pulmonary fibrosis: Pathways are slowly coming into light. Am. J. Respir. Cell Mol. Biol. 22, 520-523.
11. Daniels, J. M., Brien, J. F., and Massey, T. E. (1989). Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol. Appl. Pharmacol. 100, 350-359.
12. 2+ on substrate utilization. Biochemistry 12, 1438-1445.
13. Fromenty, B., Fisch, C., Berson, A,, Letteron, P., Larrey, D., and Pessayre, D. (1990). Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 255, 1377-1384.
14. Gross, T. J., and Hunninghake, G. W. (2001). Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345, 517-525.
15. Guerreiro, M. H. C. P. M., Lopes, L. C. V., Campello, A. P., and Kluppel, M. L. W. (1986). Effect of amiodarone on mitochondrial energy-linked reactions and on mitochondrial morphology. Arq. Biol. Tecnol. 29, 621-631.
16. Haley, P. J., Muggenburg, B. A., Weissman, D. N., and Bice, D. E. (1991). Comparative morphology and morphometry of alveolar macrophages from six species. Am. J. Anat. 191, 401-407.
17. Iyer, S. N., Gurujeyalakshmi, G., and Giri, S. N. (1999). Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291, 367-373.
18. Iyer, S. N., Hyde, D. M., and Giri, S. N. (2000). Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 24, 477-491.
19. Iyer, S. N., Wild, J. S., Schiedt, M. J., Hyde, D. M., Margolin, S. B., and Giri, S. N. (1995). Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125, 779-785.
20. Kehrer, J. P., and Margolin, S. B. (1997). Pirfenidone diminishes cylophosphamide-induced lung fibrosis in mice. Toxicol. Lett. 90, 125-132.
21. Kelley, J. (1993). Cytokines of the lung. In Lung Biology in Health and Disease (C. Lenfant, Ed.), vol. 61, pp. 101-137. Marcel Dekker, Inc., New York.
22. Leeder, R. G., Evans, C. D., Brien, J. F., and Massey, T. E. (1994). Resistance of the hamster to amiodarone-induced pulmonary toxicity following repeated intraperitoneal administration. Toxicol. Lett. 74, 51-59.
23. Lindenschmidt, R. C., and Witschi, H. P. (1985). Propranolol-induced elevation of pulmonary collagen. J. Pharmacol. Exp. Ther. 232, 346-350.
24. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
25. Mason, J. W. (1987). Amiodarone. New Engl. J. Med. 316, 455-466.
26. Massey, T. E., Leeder, R. G., Rafeiro, E., and Brien, J. F. (1995). The 1994 Veylien Henderson Award of the Society of Toxicology of Canada. Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Can. J. Physiol. Pharmacol. 73, 1675-1685.
27. Mirkovic, S., Seymour, A. M., Fenning, A., Strachan, A., Margolin, S. B., Taylor, S. M., and Brown, L. (2002). Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br. J. Pharmacol. 135, 961-968.
28. Nolan, P. E., Jr., Nappi, J., and Pollak, P. T. (1998). Clinical efficacy of amiodarone. Pharmacotherapy 18, 127S-137S.
29. Oury, T. D., Thakker, K., Menache, M., Chang, L. Y., Crapo, J. D., and Day, B. J. (2001). Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am. J Respir. Cell Mol. Biol. 25, 164-169.
30. Pollak, P. T. (1999). Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations. Am. J. Cardiol. 84, 37R-45R.
31. Rafeiro, E., Leeder, R. G., Brien, J. F., Kabalka, G. W., Chatla, N., and Massey, T. E. (1994). Comparison of the in vivo pulmonary toxicity of amiodarone and des-oxo-amiodarone in the hamster. Toxicol. Appl. Pharmacol. 127, 275-281.
32. Raghu, G., Johnson, W. C., Lockhart, D., and Mageto, Y. (1999). Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159, 1061-1069.
33. Reasor, M. J., and Kacew, S. (1996). An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc. Soc. Exp. Biol. Med. 212, 297-304.
34. Selman, M., King, T. E., and Pardo, A. (2001). Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134, 136-151.
35. Shimizu, T., Kuroda, T., Hata, S., Fukagawa, M., Margolin, S. B., and Kurokawa, K. (1998). Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54, 99-109.
36. Sime, P. J., and O'Reilly, K. M. (2001). Fibrosis of the lung and other tissues: New concepts in pathogenesis and treatment. Clin. Immunol. 99, 308-319.
37. Sokal, R. R., and Rohlf, F. J. (1973). Introduction to Biostatistics. W. H. Freeman and Company, San Francisco, CA.
38. Tada, S., Nakamuta, M., Enjoji, M., Sugimoto, R., Iwamoto, H., Kato, M., Nakashima, Y., and Nawata, H. (2001). Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. 28, 522-527.
39. Taylor, M. D., Antonini, J. M., Roberts, J. R., Van Dyke, K., Bowman, L. L., Castranova, V., Hobbs, A. F., Shi, X., Leonard, S. S., and Reasor, M. J. (2001). Intratracheal amiodarone adminstration to Fischer 344 rats causes acute damage to airways and parenchymal cells; the possible role of free radical generation. Toxicologist 60, 425 (Abstract).
40. Yasuda, S. U., Sausville, E. A., Hutchins, J. B., Kennedy, T., and Woosley, R. L. (1996). Amiodarone-induced lymphocyte toxicity and mitochondrial function. J. Cardiovasc. Pharmacol. 28, 94-100.